<DOC>
	<DOCNO>NCT00355472</DOCNO>
	<brief_summary>This Phase I label dose escalation study KW-0761 relapse patient CCR4 positive Adult T-Cell Leukemia-Lymphoma ( ATL ) Peripheral T-Cell lymphoma ( PTCL ) .</brief_summary>
	<brief_title>Phase I Study KW-0761 Relapsed Patients With CCR4-Positive ATL PTCL</brief_title>
	<detailed_description>This Phase I open-label dose escalation study KW-0761 relapse patient CCR4 positive Adult T-Cell Leukemia-Lymphoma ( ATL ) Peripheral T-Cell Lymphoma ( PTCL ) . This study design evaluate safety , pharmacokinetics , immunogenicity preliminary efficacy . Enrollment proceed maximum tolerate dose ( MTD ) recommend Phase II dose ( RPIID ) establish .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<criteria>1 . Histologically confirm diagnosis CCR4positive ATL PTCL follow : A. ATL ( Adult TCell LeukemiaLymphoma ) Seropositive antiHuman Tlymphotrophic Virus typeI ( HTLVI ) antibody ; Acute , Lymphoma , Chronic phase highrisk factor ( within 14 day study entry ) ; B. PTCL ( Peripheral TCell Lymphoma ) Includes Mycosis Fungoides Sezary Syndrome ; 2 : Relapsed late standard chemotherapy ; 3 : Received least one prior chemotherapy ; 4 : After 4 week prior therapy ; 5 : Have measurable disease ; 6 : Eastern Cooperative Oncology Group ( ECOG ) Performance Status score 0 1 ; 7 : Male female , least 20 year old 70 year age ; 8 : Signed write informed consent ; 9 : Stay hospital 4 week ; 10 : HBs antigen : negative , HBVDNA : limit quantification ( within 14 day study entry ) ; 11 : Adequate bone marrow , hepatic cardiac function include following : Neutrophil count ≥ 1,500 /mm3 , Platelets ≥ 75,000 /mm3 , Hemoglobin ≥ 8.0 g/dL Serum creatinine ≤ 1.5 x ULN ; Serum SGOT ( AST ) SGPT ( ALT ) ≤ 2.5 x ULN ( ≤ 5.0 x ULN consider due disease involvement liver ) ; Serum bilirubin ≤ 1.5 x ULN ( ≤ 3.0 x ULN consider due disease involvement liver ) Serum calcium ≤ 11.0 mg/dL PaO2 ≥ 65 mmHg SaO2 ≥ 90 % No clinically significant Electrocardiogram abnormality Left Ventricular Ejection Fraction ≥ 50 % [ ECHO MUGA ] 1 . Coexisting active infection coexist medical condition may compromise safety patient study , affect patient 's ability complete study , interfere interpretation study result ; 2 . Active tuberculosis ; 3 . Prior stem cell transplantation ; 4 . Myocardial infarction ( within 12 month prior study entry ) ; 5 . Concurrent acute chronic hepatitis , cirrhosis ; 6 . AntiHCV : positive , AntiHIV : positive 7 . Concurrent active malignant disease ; 8 . Known allergic reaction antibody therapy ; 9 . Concomitant treatment systemic steroid ; 10 . Prior Concurrent psychiatric disorder include dementia , epilepsy CNS diseases ; 11 . Evidence CNS metastasis baseline ; 12 . Prior Concurrent spinal cord disease ; 13 . Radiation therapy bulky mass disease time study entry consider require radiation therapy study ; 14 . Female patient pregnant breast feeding ; 15 . Female patient childbearing potential , unwilling use approve , effective mean contraception accordance institution 's standard ; 16 . Treatment investigational agent within 4 month prior study entry ; 17 . For reason judge Investigator inappropriate study participation , include inability communicate cooperate Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Adult T-Cell Leukemia</keyword>
	<keyword>ATL</keyword>
	<keyword>Adult Peripheral T-Cell Lymphoma</keyword>
	<keyword>PTCL</keyword>
</DOC>